Anebulo Pharmaceuticals, Inc.
1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
United States
(512) 598-0931
https://www.anebulo.com
版塊: Healthcare
行業: Biotechnology
全職員工: 2
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman | 11k | 無 | 1972 |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer | 425.15k | 無 | 1959 |
| Mr. Richard Anthony Cunningham | CEO & Director | 無 | 無 | 1971 |
| Mr. Daniel V. George | Principal Accounting Officer, Acting CFO & Secretary | 無 | 無 | 1970 |
| Mr. Scott L. Anderson | Head of Investor Relations & Public Affairs | 無 | 無 | 無 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
公司管治
截至 無 止，Anebulo Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
